A major goal of immunotherapy remains the control of pathogenic T cell responses that drive autoimmunity and allograft rejection. Adherent progenitor cells, including mesenchymal stromal cells (MSCs) and multipotent adult progenitor cells (MAPCs), represent attractive immunomodulatory cell therapy candidates currently active in clinical trials. MAPCs can be distinguished from MSCs on the basis of cellular phenotype, size, transcriptional profile, and expansion capacity. However, despite their ongoing evaluation in autoimmune and allogeneic solid organ transplantation settings, data supporting the immune regulatory potential of clinical-grade MAPCs are limited. In this study, we used allogeneic islet transplantation as a model indication to assess the ability of clinical-grade MAPCs to control T cell responses that drive immunopathology in human autoimmune disease and allograft rejection. MAPCs suppressed T cell proliferation and Th1 and Th17 cytokine production while increasing secretion of IL-10 and were able to suppress effector functions of bona fide autoreactive T cells from individuals with type 1 diabetes mellitus, including killing of human islets. Furthermore, MAPCs favored the proliferation of regulatory T cells during homeostatic expansion driven by g-chain cytokines and exerted a durable, yet reversible, control of T cell function. MAPC suppression required licensing and proceeded via IDO-mediated tryptophan catabolism. Therefore, the common immune modulatory characteristics of clinical-grade MAPCs shown in this study suggest that they can be regarded as an alternative source of adult progenitor cells with similar clinical usefulness to MSCs. Taken collectively, these findings may guide the successful deployment of both MSCs and MAPCs for the amelioration of human autoimmunity and allograft rejection. The Journal of Immunology, 2013, 190: 4542-4552.
A major goal of immunotherapy remains the control of pathogenic T cell responses that drive autoimmunity and allograft rejection. Although systemic immune suppression provides an indispensable means of controlling otherwise hazardous T cell responses, long-term use of these agents is undesirable because of malignancies, toxic drug interactions, and opportunistic infection. Cellular therapies represent an emerging class of alternative treatment options with the capacity to provide context-dependent and site-specific immunomodulation. Adherent stem and progenitor cells, which can be isolated from a variety of tissues and expanded ex vivo, are one candidate cell therapy currently active in clinical trials; a prototype is the mesenchymal stromal cell (MSC). Isolation and culture conditions can influence properties of this class of cell, notably with respect to expansion capacity and progression to terminal differentiation. Independent of tissue source, cells within this class share immunomodulatory properties that are well documented in recent reviews (1) (2) (3) . Multipotent adult progenitor cells (MAPCs) are a population of adherent progenitor cells isolated from adult bone marrow that meet the International Society for Cellular Therapy criteria applied to MSC as a prototype for adherent stem and progenitor cells (i.e., expressing CD73 and CD105, negative for MHC class II and CD45, and capable of differentiation to mesenchymal lineages) (4, 5) . Compared with standard MSC culture conditions, MAPCs are isolated using hypoxic conditions in media supplemented with growth factors (epidermal growth factor and platelet-derived growth factor) and kept at subconfluent culture density (6) (7) (8) . These conditions maintain expression of telomerase, leading to an increase in expansion capacity prior to senescence, a finding that is consistent with the reported use of forced telomerase expression in standard MSC culture (9) . This may be advantageous in a translational context, because it enables clinical manufacturing through the creation of a master cell bank and production of uniform clinical doses without the use of multiple donors. Clinical-grade MAPCs have been isolated using these conditions and are currently active in phase II clinical development as an "off-the-shelf" infused cell product for ulcerative colitis and ischemic stroke (10) . A single master cell bank has been sufficient to support these and previous phase I studies in acute myocardial infarction and allogeneic bone marrow transplant in which all doses were safe and well tolerated (10, 11) . However, despite their ongoing evaluation in autoimmune and allogeneic solid organtransplantation settings, data supporting the immune regulatory potential of clinical-grade MAPCs are limited. An understanding of the potency, breadth, and mechanism of immune regulation conferred by these cells is essential to design parameters and infer the findings of future clinical trials.
The objectives of this study were two-fold. First, we sought to ascertain whether clinical-grade MAPCs display the immunomodulatory properties and mechanisms that are common to MSCs. Second, we wished to test the suitability of clinical-grade MAPCs for the treatment of human autoimmune disease and allograft rejection using human in vitro model systems. Therefore, we evaluated the potential for clinical-grade MAPCs to suppress physiological, Agmediated T cell responses that drive pathology in human autoimmunity and allograft rejection. To conduct this study, we used the model indication of allogeneic islet transplantation (AIT), in which graft attrition is governed by several well-defined pathological checkpoints, including both allospecific and anti-self T cell responses (12) . These include Ag-driven proliferation of allospecific and autoreactive T cells, production of pathogenic Th1 and Th17 cytokines (e.g., IFN-g, TNF-a, and IL-17), destruction of target tissue, cytokine-driven (homeostatic) proliferation of T cells, and recurrence of allo-or autoimmune responses. Given that the majority of these checkpoints are common to autoimmunity and allograft rejection, these findings may lead to new translational strategies using these adult progenitor cells or new biologics or drugs to advance this clinical setting.
Materials and Methods

MSC and MAPC cell culture
MultiStem clinical-grade MAPCs, generated by Athersys, were isolated from donor bone marrow aspirate from a 21-y-old white male. This was processed according to previously described methods (7) . Briefly, human MAPCs were isolated from a single bone marrow aspirate, obtained with consent from a healthy donor, and cultured in fibronectin-coated plastic tissue culture flasks. Cell cultures were maintained under low oxygen tension in a humidified atmosphere of 5% CO 2 Invitrogen) . Flow cytometric analysis of surface-expressed Ags confirmed that MultiStem cells used in this study were a homogenous population. The cells were positive (.90%) for CD49c and CD90 and negative (,5%) for MHC class II and CD45 (all Abs were from BD Biosciences). Cells were cryopreserved in PLASMA-LYTE A (Baxter) with DMSO and human serum albumin. Immediately prior to their use in in vitro assays, MultiStem cells were thawed and washed twice in complete culture medium. Human MSCs were isolated on plastic tissue culture flasks from the same bone marrow aspirate as the MAPCs. Cell cultures were expanded in a humidified atmosphere of 5% under normal oxygen tension. MSCs were grown to confluence in MSCGM Mesenchymal Stem Cell Growth Medium (Lonza) before passaging. Cells were counted at every passage, and population doublings (PDs) were calculated based on the number of cells initially seeded (C i ) and the number of cells harvested (C h ) using the following equation: PD h = PD i + log 2 (C h /C i ).
Responder and stimulator cell culture
Following informed consent, PBMCs were isolated from fresh blood of healthy volunteers, therapeutically bled individuals with primary hemochromatosis, and individuals with long-standing type 1 diabetes mellitus (T1D; .3 y postdiagnosis) by density-gradient centrifugation using Lymphoprep (Axis-Shield) and cryopreserved as previously described (13) . All cells were labeled with CFSE or the Violet proliferation kit (Molecular Probes, Invitrogen), and dead cells were excluded with 7-aminoactinomycin D (Calbiochem) or Fixable Live/Dead stains (Molecular Probes, Invitrogen). Enzira vaccine preparation (Pfizer) was used as a source of recombinant hemagglutinin (HA) and human T cell expander beads (Dynal, Invitrogen) as a source of anti-CD3, anti-CD28-coated beads. Monocyte-derived dendritic cells (DCs) were generated from PBMCs by incubation for 6 d with IL-4 and GM-CSF (R&D Systems), as previously described (13) . To assess modulation of islet-specific T cell responses, PBMCs from individuals with T1D were first assessed for proliferation in response to a panel of previously described islet peptides (14) , and cocultures with MAPCs were subsequently performed with selected peptides known to elicit a proliferative response in that individual. The cytotoxic human T cell clone 1E6 specific for preproinsulin (PPI) [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] was isolated from an individual newly diagnosed with T1D, as previously described, and used as indicated in the figure legends (15) . Assays were set up using 1 3 10 5 PBMCs/well in roundbottom 96-well plates (Corning) at 37˚C, 5% CO 2 . MAPCs and stimuli were added at 0 h at the ratios indicated or as described in the figure legends. 
Flow cytometry
Cytometric bead array
Cell culture supernatants were frozen at 280˚C and analyzed using a Milliplex MAP kit and Luminex FLEXMAP 3D instrumentation (Millipore), the Enspire platform (PerkinElmer), or FlowCytomix (eBiosciences), according to the manufacturers' instructions.
Islet cell cytotoxicity assays
Human islets were isolated and cultured as described previously (15) . Cytotoxicity was analyzed by a nonradioactive Europium TDA cytotoxicity assay using DELFIA Technology (PerkinElmer), according to the manufacturers' instructions, as previously described (16, 17) .
IDO blocking and Transwell experiments
IDO-inhibition assays were carried out as indicated in the figure legends using frozen, sterile filtered stocks of 1-methyl-l-tryptophan and L-tryptophan (Sigma) prepared in 0.5 M HCl and adjusted to pH 7.4 using NaOH. Transwell cultures used 24-well plates with a 1-mM pore size insert (Corning).
Statistical analysis
Analysis of paired data was completed using one-tailed (to test hypotheses stating directional change) or two-tailed (to test hypotheses where changes may occur bidirectionally) Wilcoxon signed-rank tests (not normally distributed) or paired Student t tests (normally distributed). Unpaired groups were analyzed by an unpaired Student t test. All tests were performed, including a 95% confidence interval, using GraphPad Prism Software v5.0.
hanced replicative potential ( Fig. 1B ) and exhibited significantly higher levels of telomerase activity compared with autologous MSCs (Fig. 1C) .
MAPCs suppress T cell proliferation
Islet allograft rejection is associated with in vitro proliferative T cell responses to both allo-and autoantigen, suggesting that regulation of this immunopathological checkpoint may promote graft survival (18) . To confirm that MAPCs suppress T cell proliferation, we stimulated CFSE-labeled PBMCs in the presence of third-party clinical-grade MAPCs or MSCs derived from the same individual and measured cell division by CFSE dye dilution in gated T cell populations. T cells were initially stimulated with anti-CD3, anti-CD28-coated beads (hereafter anti-CD3/28) ( Fig.  2A-C) . However, because stimulation using immobilized Abs may not accurately emulate the complexity and nature of Agspecific responses, we also examined proliferation in response to Ags used to model allogeneic transplantation (third-party DCs) ( Fig. 2D-F ) and the effector memory responses observed in autoimmunity (influenza HA; hereafter HA) ( Fig. 2G-I ). Although there was considerable interindividual variation in the level of proliferation observed for each stimulus, MAPCs and MSCs significantly inhibited proliferation of both CD4 and CD8 T cells under all conditions. There was no significant difference in the level of suppression by MSCs compared with MAPCs for any of the culture conditions. MAPCs were nonimmunogenic in unstimulated cocultures (Supplemental Fig. 1A ) and suppressed T cell proliferation in a dose-dependent manner (Supplemental Fig.  1B-E) . Furthermore, multiple batches of MAPCs demonstrated similar levels of suppression, irrespective of donor origin or lot (Supplemental Fig. 1F ), whereas suppression was not observed with HUVECs (Supplemental Fig. 1G ) or MAPCs fixed with PFA or formaldehyde (data not shown). To confirm the mechanism by which MAPCs suppressed T cell proliferation, CFSE dilution was measured within viable CD3 + cells of anti-CD3/28-stimulated PBMCs in the bottom chamber of a Transwell system. MAPCs were then seeded in the upper chamber in the presence or absence of resting or stimulated PBMCs. The presence of MAPCs in the upper chamber resulted in low levels of suppression compared with contact. This was augmented by the presence of unstimulated PBMCs and further enhanced when MAPCs were in contact with stimulated PBMCs, achieving a level of suppression that was not statistically significantly different from that observed under contact conditions (Fig. 3A) . Therefore, MAPCmediated T cell suppression can occur via soluble mediator(s) that are produced in response to either secreted or cell-associated molecules expressed by proximal, activated PBMCs. Because the catabolic enzyme IDO has been implicated in MSC-mediated T cell suppression, we next blocked the IDO pathway with the chemical inhibitor 1-methyl tryptophan (1-MT) or supplemented MAPC-PBMC cocultures with L-tryptophan to compensate for IDO-mediated tryptophan catabolism. Both 1-MT and L-tryptophan were sufficient to reverse the majority of MAPC-mediated suppression, suggesting that IDO-mediated tryptophan catabolism is largely accountable for MAPC-mediated T cell suppression in anti-CD3/28-stimulated cultures (Fig. 3B ). In line with these findings, both rIFN-g and supernatant of stimulated PBMC cultures were sufficient to induce IDO1 gene expression in MAPCs .100,000-fold (data not shown). Suppression of T cell proliferation did not result in increased levels of T cell apoptosis or necrosis and was independent of PGE 2 synthesis (Supplemental Fig. 2) . 
MAPCs suppress production of pathogenic but not protective cytokines
The elicitation of pathogenic T cell responses requires the presence of antigraft and antiself T cell pools, as well as a bias in effector function. For example, islet-specific CD4 T cells found in individuals with newly diagnosed T1D primarily secrete proinflammatory cytokines (e.g., IFN-g), and recent data also suggest a role for islet-specific Th17 CD4 T cells in the augmentation of b cell apoptosis in T1D (19) . In contrast, islet-specific responses in healthy individuals are dominated by IL-10 production from cells with a potent regulatory phenotype (14, 20) . Likewise, graft destruction in AIT is associated with increased frequencies of proinflammatory alloantigen-specific T cells and the loss of IL-10 production (21-23) . Thus, redressing the balance of pathogenic (IFN-g/IL-17) and protective (IL-10) cytokines during responses to allo-or autoantigen is a desirable property for interventions targeting islet allograft rejection. Therefore, we examined the potential for MAPCs to regulate effector and regulatory cytokine production in our Ag-driven (DC and HA) models of allogeneic and effector memory responses. Analysis of PBMC coculture supernatants revealed that IFN-g was significantly suppressed by MAPCs and MSCs, whereas IL-10 production was increased under both stimulation conditions and to a greater extent by MSCs (Fig. 4A, 4B ). However, because we did not reproducibly observe detectable levels of IL-17 in culture supernatants, we also chose to measure pathogenic cytokine production by ICS following restimulation with PMA and ionomycin after the initial culture with DCs or HA. Gating on CFSE lo cells enabled us to assess cytokine production in responding, Ag-specific T cells. In this assay system, both DC-and HA-specific IFN-g and IL-17 production was significantly suppressed, with similar potency observed for MAPCs and MSCs (Fig. 4C-F) . IFN-g and TNF-a secretion was also suppressed in CD8 T cells, whereas similar results were obtained using MSCs and MAPCs at lower ratios (1:10) of progenitor cells/PBMCs (data not shown). Therefore, like MSCs, MAPCs suppress pathogenic Th1 and Th17 cytokine production during Agdriven T cell responses while enhancing IL-10.
MAPCs suppress proliferation and effector function of islet-specific autoreactive T cells from individuals with T1D
Autoreactive T cell responses of individuals with T1D (such as those receiving islet allografts) have been reported to exhibit resistance to regulatory T cell (Treg)-mediated suppression (24, 25) . Therefore, we examined whether MAPCs could suppress proliferation of islet-specific CD4 T cells from individuals with T1D. MAPCs significantly suppressed proliferation of autoreactive effector T cells in response to their natural autoantigenic peptides (Fig. 5A-C) ; however, because of the low frequency and magnitude of these responses, we were unable to measure cytokine production in this system. Therefore, we also examined the ability of MAPCs to modulate cytokine production and cytolytic effector function of highly activated autoreactive CTLs using a PPIspecific CTL clone (1E6) that exhibits a TNF-a-dependent cytotoxicity of human islets (15) . MAPCs potently inhibited cytokine production (Fig. 5D, 5E ) and, at higher ratios, reduced the ability of the clone to kill human islets (Fig. 5F ). These results indicate that MAPCs can suppress proliferation, cytokine secretion, and killing of bona fide autoreactive T cells from individuals with T1D, potentially leading to increased survival of target tissue.
MAPCs suppress g-chain cytokine-dependent proliferation of T cells
Immune suppression regimens to prevent allograft rejection involve lymphodepleting induction therapy and the subsequent use of agents to target T cell proliferation. Lymphocyte reconstitution following induction therapy occurs via homeostatic proliferation (HP) of spared, pre-existing T cell pools in a process that requires g-chain cytokines (typically IL-7 and IL-15 (Fig. 6C, 6D ), suggesting that MAPCs may selectively favor the outgrowth of Tregs in vitro. No differences were observed in the suppression of HP by MAPCs compared with autologous MSCs, confirming that modulation of cytokine-driven proliferation is a common feature of MSCs and MAPCs (Supplemental Fig. 3 ).
MAPCs exert durable T cell suppression
We next sought to examine whether coculture with MAPCs resulted in durable suppression that persisted when MAPCs were no longer present. Given the reported short t 1/2 of MSCs in vivo, this is a key question that has implications for repeat-dosing regimens and discerning therapeutic mechanisms of progenitor cells in vivo (32, 33) . We reasoned that, if MAPCs imposed a durable suppression of proliferation, exposure to MAPCs during primary stimulation would result in reduced proliferation during secondary restimulation, even when the MAPCs were no longer present. We tested this by sorting both "resting" CFSE hi cells from PBMCs previously cultured in the presence or absence of MAPCs and "suppressed" CFSE hi cells from cultures stimulated with DCs in the presence of MAPCs (Fig. 7A) . Resting CD4 T cells that were previously exposed to MAPCs proliferated significantly less in response to DC stimulation than did resting cells previously cultured in the absence of MAPCs (Fig. 7B) . Furthermore, "suppressed" CD4 T cells that were isolated from DC+MAPC cultures exhibited significantly lower levels of proliferation compared with both resting cells and resting cells exposed to MAPCs. Addition of exogenous IL-2 during secondary restimulation was sufficient to rescue the durable suppression observed in MAPC-exposed CD4 T cells. Although IL-2 seemed to be more effective at restoring the proliferation of cells isolated from the "resting" (+MAPC) compared with the "suppressed" (DC+MAPC) culture in individual experiments (Fig. 7A) , this was not statistically significant overall (Fig. 7B) . Cells from all cultures proliferated vigorously and to an equivalent level in response to restimulation with anti-CD3/28. Similar results were seen when using an effector-memory model of stimulation (Supplemental Fig. 4A, 4B) . Therefore, the fate of T cells previously exposed to MAPCs is a durable, yet reversible, suppression of Ag-driven proliferation that persists in the absence of MAPCs.
Discussion
Immunomodulatory progenitor cells, such as MSCs and MAPCs, continue to hold much promise for the treatment of T cell-driven immunopathology. Human MAPCs can be distinguished from human MSCs on the basis of cell surface phenotype, cell size, transcriptional profile, cytokine production, differentiation potential and replicative capacity (6, 10, 34, 35) . Previous work showed that murine MAPCs exert therapeutic immunomodulatory effects in the context of graft-versus-host disease prophylaxis, in MLR systems in vitro, and that human MAPCs prevented inflammation in a murine model of stroke, supporting a role for these cells in treating human immune-mediated diseases (36) (37) (38) .
This study demonstrates that, despite their enhanced expansion potential and phenotypic differences, clinical-grade MAPCs exhibit similar immunomodulatory characteristics and potency to MSCs, downregulating T cell proliferation and functioning, in part via IDO-mediated tryptophan catabolism (39) . This is in agreement with a recent report illustrating that human MAPCs are nonimmunogenic and suppress T cell proliferation in an IDOdependent and PGE 2 -independent manner (40) . In addition, our Transwell system reveals that maximal suppression is achievable solely by secreted factors, provided that MAPCs are in close proximity to activated PBMCs. This result aligns with several reports highlighting that MSC-mediated suppression can occur via the IDO pathway downstream of licensing signals (e.g., IFN-g) and supports the notion that MAPCs would be most suppressive in the context of an inflammatory environment/ongoing immune response (41). Consistent with this, rodent MAPCs were shown to exhibit efficacy in the context of graft-versus-host disease only when present at sites of allopriming (36) . Although implicated in MSC-mediated T cell suppression, we did not observe a role for PGE 2 in MAPC-mediated T cell suppression under any stimulation conditions. This may be due to intrinsic differences between MAPCs and MSCs or reflect differences in assay methodology (e.g., responder cell type analyzed or readout of proliferation).
In agreement with previous reports using MSCs, we demonstrate that clinical-grade MAPCs potently suppress Th1 signature cytokines while enhancing the production of IL-10. It is not clear whether the elevated levels of IL-10 seen in MSC compared with MAPC cocultures emanate from differences in IL-10 being produced by the progenitor cell types directly or results indirectly from differences in their modulation of other leukocytes. However, at lower ratios (i.e., 1:10), differences in IL-10 induction between MAPCs and MSCs were not apparent (data not shown). Although IL-10 induction and Th1 cytokine suppression are regarded as consensus properties for MSCs, suppression of Th17 cells remains more contentious, with discordant reports proposing that MSCs can enhance or inhibit Th17 expansion (42) (43) (44) (45) (46) (47) (48) . It was suggested that this may reflect the influence of a network of interdependent variables, such as donor, cell type, licensing, T cell activation status, level of contact, and balance in Th17-enhancing (i.e., TGF-b/IL-6) versus inhibitory (e.g., IDO, PGE 2 ) factors (3, 41) . Although, overall, we observed suppression of IL-17 production, we identified a small proportion of individuals (one of seven donors tested) in whom MAPC coculture led to increased IL-17 expression following both DC and HA stimulation, despite the suppression of IFN-g under the same conditions (Supplemental Fig. 4C, 4D) . Thus, this result reaffirms that interdonor variation may account for some of the discrepancies observed in previous reports examining IL-17.
In agreement with Zanone et al. (49), we found that MAPCs can suppress both proliferation and cytokine production from bona fide autoreactive T cells from individuals with T1D. Our study also reveals that MAPCs can attenuate the killing potential of a highly activated autoreactive CTL clone, demonstrating that a progenitor cell therapy may be capable of preserving human target tissue from cytotoxic destruction.
In agreement with a previous report using MSCs, our HP data imply that MAPCs and MSCs attenuate, but do not abrogate, cytokine-driven T cell proliferation. Therefore, this may facilitate gradual lymphocyte reconstitution while preventing graft attrition, which is associated with rapid T cell repopulation (50) . We additionally demonstrated that MAPCs preferentially suppressed Teffs compared with Tregs during cytokine-driven proliferation, reaffirming similar findings with MSCs in Ag-driven systems (41) . Although these results remain encouraging, further in vivo investigation is required to fully discern the mechanism by which The potential for MSCs to impose durable suppression has been investigated in MLR systems, often with conflicting results that have been attributed to differences in assay design (51) (52) (53) . In our investigation, we assessed responses of suppressed cells in the absence of the potentially confounding effects of other cell types from the primary culture, allowing us to examine the long-term, CD4 T cell-intrinsic effects of MAPC suppression. Our results suggest that suppression of CD4 T cell proliferation by MAPCs imparts a cell-intrinsic long-term effect that may be bypassed when using artificial stimulation and, therefore, likely is dependent on the process of physiological Ag presentation or costimulation. Of relevance, rodent MAPCs were shown to induce CTLA-4 expression on responding T cells in MLR assays, which abrogates APCmediated costimulation but is circumvented using immobilized Abs (36) . An equally plausible explanation is that long-term effects may be overcome by signal strength, either directly through enhanced signaling or indirectly by inducing de novo synthesis of endogenous IL-2. The latter of these explanations is consistent with the reversal of durable suppression that we observed using exogenous IL-2, which remains compatible with that possibility that MAPCs cause IDO-induced T cell anergy (53, 54) . These data may explain, in part, the paradoxical longevity of immune modulation, despite the short half-life of infused MSCs in vivo, and observations from clinical trials that repeat dosing of MSCs and MAPCs does not incrementally improve therapeutic benefit (6, 33) .
Taken collectively, the data suggest that MAPCs, like MSCs, may be effective in regulating T cell responses associated with allograft rejection and autoimmunity, such as those that contribute to failure of AIT. Further preclinical investigations will substantiate whether the novel findings of direct protection of target tissue from CTL destruction, preferential HP of Tregs, and durable suppression translate to therapeutic benefit in vivo. In AIT, such effects may synergize with the established potential for MSCs to prevent b cell apoptosis, induce b cell neogenesis, and promote revascularization or organization of islet morphology (55) . This class of adherent stem and progenitor cells continues to display therapeutic efficacy in a range of clinical indications and represents a promising alternative or adjunct therapy for pharmacological immune suppression. 
